Business

Neil T. Mason, MBA, Jason M. Burkett, CPA, MACC, Ryan S. Nelson, PharmD, Julio M. Pow-Sang, MD, Robert A. Gatenby, MD, Timothy Kubal, MD, MBA, John W. Peabody, MD, PhD, G. Douglas Letson, MD, Howard L. McLeod, PharmD, Jingsong Zhang, MD, PhD

Neil T. Mason, MBA; Jason M. Burkett, CPA, MACC; Ryan S. Nelson, PharmD; Julio M. Pow-Sang, MD; Robert A. Gatenby, MD; Timothy Kubal, MD, MBA; John W. Peabody, MD, PhD; G. Douglas Letson, MD; Howard L. McLeod, PharmD; Jingsong Zhang, MD, PhD

Play Video

Business, Original Research

Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn’s Disease

Michele Wilson, MSPH, Aaron Lucas, PhD, MPH, Ann Cameron, MA, PhD, Michelle Luo, PhD

Michele Wilson, MSPH; Aaron Lucas, PhD, MPH; Ann Cameron, MA, PhD; Michelle Luo, PhD

Play Video

Business, Original Research

Budget Impact of Intravenous Cetirizine Hydrochloride for the Treatment of Acute Urticaria in the Emergency Department Setting

Lisa M. Bloudek, PharmD, MS, LoAn K. Ho, PharmD, Neha Kapur, PharmD, Lonnie D. Brent, PharmD

Lisa M. Bloudek, PharmD, MS; LoAn K. Ho, PharmD; Neha Kapur, PharmD; Lonnie D. Brent, PharmD

Play Video

Business

Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

Chakkarin Burudpakdee, PharmD, Anshul Shah, BS Pharm, MS, Vijay N Joish, PhD, Christine H. Divers, PhD, Avin Yaldo, PhD

Stakeholder Perspective

Is It Time for Risk-Sharing Contracts In Specialty Pharmacy?

by Atheer A. Kaddis, PharmD

Play Video

Business, Original Research

Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States

Kathleen F. Villa, MS, Nancy L. Reaven, MA, Susan E. Funk, MBA, Karen McGaughey, PhD, Jed Black, MD

Kathleen F. Villa, MS; Nancy L. Reaven, MA; Susan E. Funk, MBA; Karen McGaughey, PhD; Jed Black, MD

Stakeholder Perspective

Accurate Diagnosis of Chronic Diseases Can Reduce Costs and Medical Resource Utilization

James T. Kenney, RPh, MBA

by James T. Kenney, RPh, MBA

Play Video

Business

Characteristics of Academic Detailing: Results of a Literature Review

Thomas J. Van Hoof, MD, EdD, Lisa G. Harrison, MSN, Nicole E. Miller, BS, Maryanne S. Pappas, MS, Michael A. Fischer, MD, MS

Play Video

Business, Original Research

Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing

Joshua A. Roth, PhD, MHA, Theo deVos, PhD, Scott D. Ramsey, MD, PhD

Joshua A. Roth, PhD, MHA; Theo deVos, PhD; Scott D. Ramsey, MD, PhD

Play Video

Original Research, Business

Clinical and Financial Impacts of an Ambulatory Oncology Pharmacist–Based Intravenous Chemotherapy Education and Follow-Up Program

Grant W. Lee, PharmD, BCOP; Joseen J. Chundamala, PharmD; Kerri L. Monahan, PharmD; Judy J. Cho, PharmD; Lydia J. Berry, RPh, PharmD; Christine G. Cambareri, PharmD, BCOP, CSP

Play Video

Business

Communication Strategies Must Be Tailored to a Medication’s Targeted Population: Lessons from the Case of BiDil

Stakeholder Perspective

Much More than Biomarkers: Sociodemographic Variables in Personalized Medicine

Play Video

Business

Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States

Joseph Lee, PhD; Ryan Pelkey, MS; Julieanna Gubitosa, BS; Michael F. Henrick, MBA; Michael L. Ganz, MS, PhD

Stakeholder Perspective

Identifying the Most Clinically and Economically Effective Therapies for Rheumatoid Arthritis Remains a Challenge for Providers and Payers

Gary Branning, MBA